01-01-2000 | ORIGINAL ARTICLE
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)
Published in: Annals of Hematology | Issue 1/2000
Login to get access